Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells

Journal of Immunology

Volumn 177, Issue 8, 2006, Pages 5296-5306

  Sheng, Jian Rong ^a   Li, Angcheng ^a   Ganesh, Balaji B ^a   Vasu, Chenthamarakshan ^a   Prabhakar, Bellur S ^a   Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELL ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

EID: 33749526878     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.8.5296     Document Type: Article

References (65)

1. Vincent, A., J. Palace, and D. Hilton-Jones. 2001. Myasthenia gravis. Lancet 357: 2122-2128.
2. Brocke, S., C. Brautbar, L. Steinman, O. Abramsky, J. Rothbard, D. Neumann, S. Fuchs, and E. Mozes. 1988. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 82: 1894-1900.
3. Newsom-Davis, J., G. Harcourt, N. Sommer, D. Beeson, N. Willcox, and J. B. Rothbard. 1989. T cell reactivity in myasthenia gravis. J. Autoimmun. 2(Suppl): 101-408.
4. Moiola, L., M. P. Protti, A. A. Manfredi, M. H. Yuen, J. F. Howard Jr., and B. M. Conti-Tronconi. 1993. T helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann. NY Acad. Sci. 681: 198-218.
5. Rossi, M., and J. W. Young. 2005. Human dendritic cells: potent antigen-presenting cells at the crossroads of Innate and adaptive immunity. J. Immunol. 175: 1373-1381.
6. Lutz, M. B., and G. Schuler. 2002. Immature, semimature and fully mature dendritic cells: which signals induce tolerance or immunity. Trends Immunol. 23: 445-449.
7. Groux, H., N. Fournier, and F. Cottrez. 2004. Role of dendritic cells in the generation of regulatory T cells. Semin. Immunol. 16: 99-106.
8. Kuwana, M. 2002. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol. 63: 1156-1163.
9. Rutella, S., and R. M. Lemoli. 2004. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol. Lett. 94: 11-26.
10. + T cells and suppresses experimental autoimmune thyroiditis. J. Immunol. 170: 5511-5522.
11. + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174: 7006-7013.
12. Bellone, M., N. Ostlie, S. Lei, and B. M. Conti-Tronconi. 1991. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the α subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21: 2303-2310.
13. Karachunski, P. I., N. Ostlie, C. Monfardini, and B. M. Conti-Fine. 2000. Absence of IFN-γ or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164: 5236-5244.
14. Drachman, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797-1810.
15. Cristadoss, P., M. Poussin, and C. Deng. 2000. Animal models of myasthenia gravis. Clin. Immunol. 2: 75-87.
16. Vincent, A. 2002. Unraveling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2: 797-804.
17. Nagane, Y., K. Utsugisawa, D. Obara, M. Yamagata, and H. Tohgi. 2003. Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis. Muscle Nerve 27: 582-589.
18. Xiao, B. G., R. S. Duan, H. Link, and Y. M. Huang. 2003. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell. Immunol. 223: 63-69.
19. Yang, H., M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss. 2005. Cathepsin S is required for murine autoimmune myasthenia gravis pathogensis. J. Immunol. 174: 1729-1737.
20. Jonuleit, H., E. Schmitt, K. Steinbrink, and A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22: 394-400.
21. Hackstein, H., A. E. Morelli, and A. W. Thomson. 2001. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22: 437-442.
22. Duan, R. S., S. B. Adikari, Y. M. Huang, H. Link, and B. G. Xiao. 2004. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10 modified, dendritic cells. Neurobiol. Dis. 16: 461-467.
23. Duan, R. S., H. Link, and B. G. Xiao. 2005. Long-term effects of IFN-γ, IL-10, and TGF-β-modulated dendritic cells on immune responses in Lewis rats. J. Clin. Immunol. 25: 50-56.
24. Li, L., S. Sun, X. Cao, Y. Wang, L. Chang, and X. Yin. 2005. Experimental study on induction of tolerance to experimental myasthenia gravis by immature dendritic cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25: 215-218.
25. Reis e Sousa, C. Dendritic cells in a mature age. 2006. Nat. Rev. Immunol. 6: 476-483.
26. Wakkach, A., N. Fournier, V. Brun, J. P. Breittmayer, F. Cottrez, and H. Groux. 2003. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617.
27. + dendritic cells are generated from CD4 (low) lymphoid-committed precursors. Blood 96: 2511-2519.
28. Penna, G., M. Vulcano, S. Sozzani, and L. Adorini. 2002. Differential migration behavior and chemokine behavior by myeloid and plasmacytoid dendritic cells. Hum. Immunol. 63: 1164-1171.
29. O'Keefe, M., H. Hochrein, D. Vremec, J. Pooley, R. Evans, S. Woulfe, and K. Shortman. 2002. Effects of administration of progenipoietin 1, Flt3 ligand, granulocyte colony-stimulating, and pegylated granulocyte colony-stimulating factor on dendritic cell subsets in mice. Blood 99: 2122-2130.
30. Maraskovsky, E., B. Pulendran, K. Brasel, M. Teepe, E. R. Roux, K. Shortman, S. D. Lyman, and H. J. McKenna. 1997. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv. Exp. Med. Biol. 417: 33-40.
31. Mosley, R. L., P. Parajuli, V. Pisarev, J. Chavez, A. Meeks, A. Steffel, C. Leutzinger, and J. E. Talmadge. 2002. Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells. Int. Immunopharmacol. 2: 925-940.
32. - dendritic cells in the induction of primary immune responses in vivo. J. Leukocyte Biol. 66: 242-246.
33. - dendritic cells to prime Th1/Th2 cells in vivo. J. Immunol. 167: 4345-4350.
34. Crane, I. J., and J. V. Forrester. 2005. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 25: 75-102.
35. Kroemer, G., F. Hirsch, A. Gonzalez-Garcia, and C. Martinez. 1996. Differential involvement of Th1 and Th2 cytokines in autoimmune disease. Autoimmunity 24: 25-33.
36. Daro, E., E. Butz, J. Smith, M. Teepe, C. R. Maliszewski, and H. J. McKenna. 2002. Comparison of the functional properties of murine dendritic cells generated in vivo with flt3 ligand, GM-CSF and flt3 ligand plus GM-CSF. Cytokine 17: 119-130.
37. lowCD11chigh murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165: 49-58.
38. Dogan, R. N., C. Vasu, M. J. Holterman, and B. S. Prabhakar. 2003. Absence of IL-4, and not suppression of the Th2 response, prevents the development of experimental Graves' disease. J. Immunol. 170: 2195-2204.
39. Karachunski, P. I., N. S. Ostlie, D. K. Okita, and B. M. Conti-Fine. 1997. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100: 3027-3035.
40. Moiola, L., F. Galbiati, G. Martino, S. Amadio, E. Brambilla, G. Comi, A. Vincent, L. M. Grimaldi, and L. Adorini. 1998. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody mediated disease. Eur. J. Immunol. 28: 2487-2497.
41. Balasa, B., J. Deng Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick. 1997. Interferon γ(IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186: 385-391.
42. Christadoss, P., and E. Goluszko. 2002. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J. Neuroimmunol. 122: 186-190.
43. Duan, R. S., H. B. Wang, J. S. Yang, B. Scallon, H. Link, H., and B. G. Xiao. 2002. Anti-TNF-α antibodies suppress the development of experimental autoimmune myasthenia gravis. J. Autoimmun. 19: 169-174.
44. McKenna, H. J., B. Balasa, and N. Sarvetnick. 2000. Is pathogenic humoral autoimmunity a Th1 response: lessons from (for) myasthenia gravis. Immunol. Today 21: 19-23.
45. + epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95: 73-84.
46. -/- BALB/c mice suggests a pathogenic role of Th1 cells. J. Immunol. 172: 97-103.
47. Banchereau, J., F. Briere, Y. J. Liu, and F. Rousset. 1994. Molecular control of B lymphocyte growth and differentiation. Stem Cells 12: 278-288.
48. Zhang, G. X., B. G. Xiao, L. Y. Yu, P. H. van der Meide, and H. Link. 2001. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113: 10-18.
49. Ostlie, N. S., P. I. Karachunski, W. Wang, C. Monfardini, M. Kronenberg, and B. M. Conti-Fine. 2001. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. 166: 4853-4862.
50. + regulatory cells. Proc. Natl. Acad. Sci. USA 102: 10285-10290.
51. + T cells in myasthenia gravis patients with stability and thymectomy. Clin. Immunol. 112: 284-289.
52. + regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J. Exp. Med. 196: 247-253.
53. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172: 5213-5221.
54. Veldman, C., A. Nagel, and M. Hertl. 2006. Type I regulatory T cells in autoimmunity and inflammatory diseases. Int. Arch. Allergy Immunol. 140: 174-183.
55. Cassese, G., S. Arce, A. E. Hauser, K. Lehnert, B. Moewes, M. Mostarac, G. Muehlinghaus, M. Szyska, A. Radbruch, and R. A. Manz. 2003. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171: 1684-1690.
56. Deng, C., E. Goluszko, E. Tuzun, H. Yang, and P. Christadoss. 2002. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169: 1077-1083.
57. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. J. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 44: 235-238.
58. Tato, C. M., and J. J. O'Shea. 2006. What does it mean to be just 17? Nature 44: 166-168.
59. Engel, A. G., and K. Arahata. 1987. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann. NY Acad. Sci. 505: 326-332.
60. Engel, A. G., E. H. Lambert, and F. M. Howard. 1977. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52: 267-280.
61. Sahashi, K., A. G. Engel, J. M. Linstrom, E. H. Lambert, and V. A. Lennon. 1978. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol 37: 212-223.
62. Biesecker, G., and C. M. Gomez. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with fab antibody to complement C5. Immunology. 142: 2654-2659.
63. Lennon, V. A., M. E. Seybold, J. M. Lindstrom, C. Cochrane, and R. Ulevitch. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147: 973-983.
64. Tuzun, E., B. G. Scott, E. Goluszko, S. Higgs, and P. Christadoss. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171: 3847-3854.
65. Drachman, D. B., K. R. McIntosh, and B. Yang. 1998. Factors that determine the severity of experimental myasthenia gravis. Ann. NY Acad. Sci. 841: 262-282.